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Postmenopausal women with elevated levels of serum sex steroid hormones including estradiol, 
testosterone, and estrone, are at increased risk for developing breast cancer. Currently, medications 
to inhibit or block estrogens are the mainstay of treatment for women with hormone receptor-positive 
breast cancer. However, data on the association between circulating sex steroid hormones and 
prognosis in breast cancer survivors are limited. To address this question Drs. Catherine Duggan, 
Anne McTiernan, and colleagues, evaluated the association between sex hormone-binding globulin 
(SHBG), and circulating levels of free (non SHBG-bound) and total estradiol, estrone, and 
testosterone, with breast cancer-specific and all-cause mortality. This association was explored in 
the Health Eating Activity and Lifestyle (HEAL) study, a multiethnic cohort of breast cancer survivors, 
diagnosed with Stage I– IIIA breast cancer. They reported their results recently in Breast Cancer 
Research and Treatment.  
The study included 358 postmenopausal women, not taking hormone replacement therapy at the 
time of blood draw, diagnosed with stage I-IIIA breast cancer between 1995 and 1998. Women were 
followed through December 2012. The investigators measured levels of estradiol, estrone, 
testosterone, and sex hormone-binding globulin (SHBG), in serum collected on average 30 months 
after diagnosis. 
Then using Cox proportional hazards models, a statistical technique for exploring the relationship 
between the survival of a patient and several explanatory variables, the authors examined the 
associations between these hormones and breast cancer-specific and all-cause mortality. Over a 
median of 14.5 years of follow-up, 102 deaths occurred; 43 of these were due to breast cancer. In 
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models controlling for ethnicity/study site, age, body mass index, and tumor stage, increased levels 
of SHBG (log transformed) were associated with reduced risk of both breast cancer-specific mortality 
(hazard ratio, HR 0.48; 95 % confidence interval, CI 0.26– 0.89) and all-cause mortality (HR 0.64, 95 
% CI 0.43– 0.97). There were no statistically significant associations between levels of estradiol, 
estrone, or testosterone for either endpoint. In subgroup analyses, after correction for multiple 
testing, increased estrone was significantly associated with reduced risk for breast cancer-specific 
mortality among participants with ER-negative tumors (HR 0.16, 95 % CI 0.05– 0.63) but not among 
participants with ER-positive tumors.  
Dr. McTiernan notes, "The most striking thing in the data was that the pattern we usually see of 
cross-the-board increase in breast cancer risk with increasing estrogen and testosterone levels was 
not seen here at all. Rather, the trend was to no associations with survival, or to improved survival 
with higher estrogen and testosterone levels. This suggests that there are differences between 
carcinogenesis and the processes that lead to fatal disease." One theory the authors cite for the 
observation that elevated levels of SHBG are associated with reduced risk of breast cancer-
associated and all-cause mortality, is the fact that bioavailable concentrations of estrogens and its 
access to target cells are regulated by SHBG. In addition SHBG may have direct effects on cells, 
mediated by its unliganded binding to a cell-membrane receptor.  Activation of the receptor– SHBG 
complex by binding to estradiol induces a number of downstream effects, including inhibition of 
progesterone receptor expression, increased apoptosis, and regulation of cell growth.  
Dr. McTiernan elaborates, "It was interesting to see that increased levels of SHBG were associated 
both with breast cancer specific and all-cause mortality.  We and others have shown that SHBG can 
be modified by diet and exercise. We’ve shown that it increases significantly with weight loss of just 
5% of starting weight and increases even more with 10% weight loss. It also increases significantly 
with a regular moderate intensity physical activity program. So this could be a potential way for 
breast cancer survivors to improve their health." 
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